[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367664-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367664-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-and-benign-tumors-in-myotonic-dystrophy-facioscapulohumeral-muscular-dystrophy-and-oculopharyngeal-muscular-dystrophy-a-23-year-single-center-retrospective-study","Cancer and benign tumors in myotonic dystrophy, facioscapulohumeral muscular dystrophy, and oculopharyngeal muscular dystrophy - a 23-year, single-center, retrospective study","","Cancer and benign tumors were investigated across adults with myotonic dystrophy type 1 and 2 (DM1, DM2), facioscapulohumeral muscular dystrophy (FSHD), and oculopharyngeal muscular dystrophy (OPMD). A 23-year single-center retrospective, cross-sectional analysis (January 2000 to September 2023) evaluated cancer frequency and tumor types and compared affected versus non-affected groups by sex and age. Among included patients, a higher risk pattern emerged for non-sex-related malignancies in DM1 and for specific cancers such as melanoma in DM2 and testicular cancer in OPMD, alongside increased benign tumor risk in DM.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-and-benign-tumors-in-myotonic-dystrophy-facioscapulohumeral-muscular-dystrophy-and-oculopharyngeal-muscular-dystrophy-a-23-year-single-center-retrospective-study/367664/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-and-benign-tumors-in-myotonic-dystrophy-facioscapulohumeral-muscular-dystrophy-and-oculopharyngeal-muscular-dystrophy-a-23-year-single-center-retrospective-study/367664.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study question was addressed about DM1, DM2, FSHD, and OPMD?","Question",{"text":63,"@type":64},"The study assessed the frequency and types of cancers and benign tumors in patients with DM1, DM2, FSHD, and OPMD.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and over what time period?",{"text":68,"@type":64},"It was a single-center, retrospective, cross-sectional study of patients at the institution from January 2000 to September 2023.",{"name":70,"@type":61,"acceptedAnswer":71},"What key findings were reported regarding cancer risks across the dystrophy subtypes?",{"text":72,"@type":64},"DM1 showed an increased risk of non-sex-related cancers versus non-DM cases, while melanoma was more frequent in DM2 and testicular cancer was more frequent in OPMD; DM patients also had increased risk of non-sex-related benign tumors such as skin and thyroid benign tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367664,1790496309,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":118,"preview_page_count":33,"preview_urls":144},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","2025;XLIV:49-56;  \nDOI: 10.36185/2532-1900-997  \nReceived: January 23, 2025  \nAccepted: March 17, 2025  \nCorrespondence  \nMehdi Ghasemi  \nE-mail: [mehdi.ghasemi@lahey.org](mehdi.ghasemi@lahey.org), m82 .ghasemi@gmail. com  \nHow to cite this article: Bareja N, Desai B, Vytopil M, et al. Cancer and benign tumors in myotonic dystrophy, facioscapulohumeral muscular dystrophy, andoculopharyngeal muscular dystrophy: a 23-year, singlecenter, retrospective study. Acta Myol 2025;44:49-56 . [https://doi.org/10.36185/2532-1900-997](https://doi.org/10.36185/2532-1900-997)  \n© Gaetano Conte Academy - Mediterranean Society of Myology  \n OPEN ACCESS  \nThis is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: [https://creativecommons.org/licenses/by-nc](https://creativecommons.org/licenses/by-nc)nd/4.0/deed.en  \nORIGINAL ARTICLE  \nCancer and benign tumorsin myotonic dystrophy, facioscapulohumeral muscular dystrophy, and oculopharyngeal muscular dystrophy: a 23-year, single-center, retrospective study  \nNaman Bareja1,2 , Brinda Desai2 , Michal Vytopil2 , Jayashri Srinivasan 2 , Mehdi Ghasemi2  \n1 Department of Neurology, Tufts Medical Center, Boston, MA, USA; 2 Department of Neurology, Lahey Hospital and Medical Center, Burlington, MA, USA  \nObjectives. Some muscular dystrophies, such as myotonic dystrophy type 1 and 2 (DM1 and DM2), facioscapulohumeral muscular dystrophy (FSHD), and oculopharyngeal muscular dystrophy (OPMD), are caused by genetic mutations that may affect the expression and function of various cancer-related genes. We assessed the frequency and type of cancers and benign tumors in patients with DM1, DM2, FSHD, and OPMD.  \nMethods. We conducted a single-center, retrospective, cross-sectional study on patients with DM1, DM2, FSHD, and OPMD at our institution from January 2000 to September 2023.  \nResults. Seventy seven (46 female) DM1, 20 (15 female) DM2, 40 (18 female) FSHD, and 46 (22 female) OPMD patients were included, among which 22 (28.57%), 9 (45%), 7 (17.5%), and 15 (32.61%) patients had at least one cancer, respectively. Median age (range) of patients where presence or absence of cancer was ascertained was 65 (18-87), 63.5 (45-86), 61 (27-83), and 71.5 (40-82) years, respectively (P \u003C 0.0001) . Overall, non-sex-related cancers were more frequent than sex-related cancers among all patients together. Independent to sex and age, DM1 patients had an increased risk of non-sex-related cancers compared to non-DM cases. Melanoma (P \u003C 0.01) and testicular (P \u003C 0.05) cancers were significantly more frequent in DM2 and OMPD patients, respectively. DM patients had also increased risk of non-sex related benign tumors (including skin and thyroid benign tumors) compared to non-DM patients.  \nConclusions. Our study highlights the differences in the prevalence of cancers and benign tumors among patients with DM1, DM2, FSHD, and OPMD, underscoring the potential need for regular screening for specific cancers.  \nKey words: Myotonic dystrophy, oculopharyngeal muscular dystrophy (OPMD), facioscapulohumeral muscular dystrophy (FSHD), cancer, melanoma, thyroid tumor  \nIntroduction  \nMyotonic dystrophy (DM), facioscapulohumeral muscular dystrophy (FSHD), and oculopharyngeal muscular dystrophy (OPMD) are the most common adult-onset genetic muscular dystrophies, all characterized by progressive muscle weakness and wasting 1-4. DM is a complex autosomal-dominant disorder with multisystem involvement, marked by muscle weakness, myotonia, and systemic manifestations 5 6. There are two main subtypes: (i) DM1: Caused by a CTG repeat expansion in the DMPK (DM1 protein kinase) gene 7 , and (ii)  \nDM2: Associated with a CCTG repeat expansion in the CNBP (ZNF9) gene 8. With a ","cbCaicX3QlvRkFQg","https://ap.wps.com/l/cbCaicX3QlvRkFQg","pdf",816655,"English","# Objectives\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What study question was addressed about DM1, DM2, FSHD, and OPMD?\",\"answer\":\"The study assessed the frequency and types of cancers and benign tumors in patients with DM1, DM2, FSHD, and OPMD.\"},{\"question\":\"How was the study conducted and over what time period?\",\"answer\":\"It was a single-center, retrospective, cross-sectional study of patients at the institution from January 2000 to September 2023.\"},{\"question\":\"What key findings were reported regarding cancer risks across the dystrophy subtypes?\",\"answer\":\"DM1 showed an increased risk of non-sex-related cancers versus non-DM cases, while melanoma was more frequent in DM2 and testicular cancer was more frequent in OPMD; DM patients also had increased risk of non-sex-related benign tumors such as skin and thyroid benign tumors.\"}]","Cancer and benign tumors in myotonic dystrophy, facioscapulohumeral muscular dystrophy, and oculopharyngeal muscular dystrophy - a 23-year, single-center, retrospective study | PDF",1790171864,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba6ed6a7555bc3c5504aa909c70a4ea9.webp",983,1334,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f567f72a8ce853f106b63e38f909d725.webp",982,1332,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4540798eb86b753fd1cfa6e1b971a9e4.webp",981,1331,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da29e3c06e8b357ff1e162fb597b76b8.webp",980,1330]